ERBB2 and breast cancer: Within Canada, the Institut National D’excellence en Sante et en Services Sociaux (INESSS) in Quebec issued a positive funding recommendation largely driven by acknowledging pCR as the most important primary endpoint of NAT for HER2 positive breast cancer, based on the identical data reviewed by CADTH [25].